Opsin-binding ligands, compositions and methods of use

A method of inhibiting the formation or accumulation of a visual cycle product or of treating an ophthalmic condition in a subject at risk thereof, comprising contacting an opsin protein with a compound having the structure of Formula I

• wherein X is:
• 1) C(Ri)(Rj), or
• 2) oxygen;
• T is:
• 1) CH2,
• 2) CH2CH2, or
• 3) absent;
• R1 and R2 are independently:
• 1) —CH3, or
• 2) —CH2CH3;
• R3 is:
• 1) hydrogen,
• 2) —CH3, or
• 3) —CH2CH3;
• R4 is:
• 1) hydrogen, or
• 2) —CH3;
• Ra and Rb are each independently:
• 1) hydrogen,
• 2) —CH3, or
• 3) —CH2CH3;
• Ri and Rj are each independently:
• 1) hydrogen,
• 2) deuteron,
• 3) hydroxyl,
• 4) fluoro,
• 5) alkoxy,
• 6) lower alkyl, or
• 7) lower haloalkyl;
• or Ri and Rj can be taken together as oxo (═O):
• B is:
• Re, Rf, Rg, Rh and Rk are each independently:
• 1) hydrogen,
• 2) lower alkyl,
• 3) lower haloalkyl,
• 4) halogen,
• 5) nitro,
• 6) hydroxy,
• 7) alkoxy,
• 8) nitrile,
• 9) carboxamido,
• 10) arylcarbonyl,
• 11) carbamoyl,
• 12) amidyl,
• 13) amino,
• 14) alkylcarbonyl, or
• 15) urea or
• 16) —C(NOH)NH2;
• Rl, Rm and Rn are:
• 1) —CRe, or
• 2) nitrogen;
• but wherein at least one of Rl, Rm and Rn is nitrogen,
• Z is:
• 1) oxygen, or
• 2) sulfur;
• including pharmaceutically acceptable salts, solvates and hydrates thereof.